comprehensive -WSS

comprehensive

author：comprehensive 2025-08-28 13:05:44 - browse：3229

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Study: Hearing aids may slow cognitive decline in those at risk

WSS

Was Amgen transparent enough on FDA's concern on cancer drug?

Biden administration sends mixed signals on US soldier who crossed into North Korea

Sana to lay off nearly a third of staff, de

Physician executives need more than on

Sana to lay off nearly a third of staff, de

A Theranos scientist

knowledge

comprehensive

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

House passes resolution saying Israel isn't a 'racist or apartheid state'

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Biden administration sends mixed signals on US soldier who crossed into North Korea

At least 13 dead in Texas as scorching temps continue

Lack of darker skin in textbooks, journals harms patients of color

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why age limits for politicians are a terrible idea

Duchenne breakthrough therapy leaves behind pioneering families

A Theranos scientist

focus

Johnson & Johnson sues to stop Medicare negotiation

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

UK homeowners get some respite as inflation falls by more than anticipated to a 15

FDA panel signals lack of confidence in Amgen cancer drug data

ER docs worry over extreme heat as a 'mass casualty event'

Analysis of telehealth claims data suggest service duplication

focus

explore

knowledge

explore